This will be the first time a cannabis-based drug has been approved anywhere in the world, representing a landmark for GW Pharma and for patients with MS. Cannabis hopes for drug firmA prescription cannabis drug made by UK biotech firm GW Pharmaceuticals is set to be approved in Canada. But now Canadian authorities have said the Sativex drug will be considered for approval. The UK government granted GW Pharma a licence to grow the cannabis plant for medical research purposes. "We are delighted to receive this qualifying notice from Health Canada and look forward to receiving regulatory approval for Sativex in Canada in the early part of 2005," said GW Pharma executive chairman Dr Geoffrey Guy. Now, GW Pharma's Sativex mouth spray could be legally available to MS sufferers in Canada within the next few months.